gene polymorphisms: biomarkers for the development and progression of breast cancerBreast cancer is a major cause of cancer mortality worldwide. Fascin-1 (FSCN1) is an actin-binding protein found in mammalian cells, including endothelial, neuronal and mesenchymal cells. FSCN1 overexpression has been...
Described herein is the use of Agouti Signaling Protein (ASIP), in addition to certain other melanocortin signaling network (MSN) genes, as prognostic and predictive biomarkers for the progression of breast cancer. In particular, the novel biomarkers can be used to determine if a female breast ...
Breast cancer is a major cause of cancer mortality worldwide. Fascin-1 (FSCN1) is an actin-binding protein found in mammalian cells, including endothelial, neuronal and mesenchymal cells. FSCN1 overexpression has been indicated in breast cancer patients. However, scant information is available regar...
Current and emerging biomarkers in breast cancer Biomarkers for breast cancer diagnosis and treatment Biomarkers for the following: patient suitability for treatment screening, prognosis, response to treatment, monitoring of disease progression, and relapse ...
gene polymorphisms: biomarkers for the development and progression of breast cancer Jin L, Wang Q, Li X, Hu GN, Huang BF, Zhao YM, Su CM: FSCN1 gene polymorphisms: biomarkers for the development and progression of breast cancer... CQ Wang,CH Tang,Y Wang,... - 《Scientific Reports》 ...
Breast cancer is one of the most common cancers in women around the world and the second leading cause of cancer death worldwide. MicroRNAs (miRNAs) expression participates in breast cancer progression. The aim of this study is to invest... Y Singh,N Subbarao,A Jaimini,... 被引量: 0发表...
Low molecular weight (LMW) peptides have been discovered that are indicative of breast cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting breast cancer and monitoring the progression of the disease, for example during treatment. The LMW ...
Fig. 1.Application different biomakers for different stages of cancer progression. Biomakers may be applied to risk assessment, early detection, determining the mechanism of cancer development, response to theraphy and cancer recurrence. View article ...
Prostate cancer (PCa) is the most common male cancer in the United Kingdom and we aimed to identify clinically relevant biomarkers corresponding to stage progression of the disease. Methods: We used enhanced proteomic profiling of PCa progression using iTRAQ 3D LC mass spectrometry on high-quality...
MUC1 and glycan probing of CA19-9 captured biomarkers from cyst fluids and serum provides enhanced recognition of ovarian cancer Shamima Afrin Ruma Rufus Vinod Kamlesh Gidwani ResearchOpen Access25 Jan 2025Scientific Reports Volume: 15, P: 3171 ...